Polydex Pharmaceuticals Stock Beta
| POLXFDelisted Stock | USD 1.96 0.01 0.51% |
Polydex Pharmaceuticals fundamentals help investors to digest information that contributes to Polydex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Polydex Pink Sheet. The fundamental analysis module provides a way to measure Polydex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Polydex Pharmaceuticals pink sheet.
Polydex |
Polydex Pharmaceuticals Company Beta Analysis
Polydex Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Polydex Pharmaceuticals Beta | 0.33 |
Most of Polydex Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Polydex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Polydex Pharmaceuticals has a Beta of 0.3337. This is 61.2% lower than that of the Pharmaceuticals sector and 75.99% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Polydex Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Polydex Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Polydex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Polydex Pharmaceuticals by comparing valuation metrics of similar companies.Polydex Pharmaceuticals is currently under evaluation in beta category among its peers.
As returns on the market increase, Polydex Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Polydex Pharmaceuticals is expected to be smaller as well.
Polydex Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0824 | |||
| Profit Margin | (0.25) % | |||
| Operating Margin | (0.22) % | |||
| Current Valuation | 2.23 M | |||
| Shares Outstanding | 3.43 M | |||
| Number Of Shares Shorted | 11 | |||
| Price To Earning | 12.33 X | |||
| Price To Book | 0.42 X | |||
| Price To Sales | 0.51 X | |||
| Revenue | 4.05 M | |||
| Gross Profit | 970.3 K | |||
| EBITDA | (568.16 K) | |||
| Cash And Equivalents | 870.3 K | |||
| Cash Per Share | 0.25 X | |||
| Total Debt | 301.49 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 5.88 X | |||
| Book Value Per Share | 1.44 X | |||
| Cash Flow From Operations | (238.54 K) | |||
| Short Ratio | 0.02 X | |||
| Earnings Per Share | (0.13) X | |||
| Number Of Employees | 21 | |||
| Beta | 0.33 | |||
| Market Capitalization | 2.23 M | |||
| Total Asset | 6.56 M | |||
| Retained Earnings | (19.53 M) | |||
| Working Capital | 2.12 M | |||
| Current Asset | 3.41 M | |||
| Current Liabilities | 1.28 M | |||
| Z Score | 1.4 |
About Polydex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Polydex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Polydex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Polydex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |